普洛藥業(000739.SZ):獲相關新冠口服藥物在指定區域內的非獨家許可
格隆匯3月18日丨普洛藥業(000739.SZ)公佈,近日,MPP(即“藥品專利池組織”)發佈公吿及相關媒體報道,MPP授權普洛藥業等35家藥企生產輝瑞公司口服新冠治療藥物。
根據簽訂的《許可協議》,其主要內容如下:
基於《許可協議》,MPP授予公司在區域內(即印度、巴基斯坦、越南等95箇中低收入國家/地區)使用相關專利和專有技術對Nirmatrelvir原料藥及Nirmatrelvir/Ritonavir專利授權制劑(原料藥和製劑以下統稱“合作產品”)開展生產、商業化及相關權利的非獨家、不可轉讓、不可分包及特許權使用費許可。
根據約定,公司將在經SRA(嚴格監管機構)批准或通過WHO(世界衞生組織)預審合格的生產設施進行合作產品的生產。
基於《許可協議》,公司生產的合作產品可以根據要求供應給輝瑞和其他MPP的專利許可受讓方,公司也可以從其他MPP專利許可受讓方採購所需的合作產品。
專利許可使用費:基於《許可協議》,在協議中規定的低收入區域(LIC)內,公司無需根據製劑銷售額支付專利許可使用費;在協議中規定的低收入區域以外的區域內,根據購買方性質的不同,公司將按照年度淨銷售額(定義依據協議)的5%或10%向輝瑞支付專利許可使用費。在WHO宣佈COVID-19不再被列為國際關注的突發公共衞生事件(包括當月)之前,上述區域內將暫停專利許可使用費義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.